# PRD 2: Precision R&D Pipeline

## 1. Product vision

Build a precision-focused AI drug discovery workflow for teams that need a chemically and biologically credible path from early target hypothesis to lead validation. This product is optimized for higher-confidence decision-making and fewer false positives, even if the throughput is lower than a high-speed platform.

## 2. Product positioning

This product emphasizes:

- strong biological validation at the early stage
- orthogonal assay reasoning
- clear selectivity and retained-activity testing
- risk-aware ADMET and toxicity screening before large synthesis commitments
- slower but higher-confidence development cycles

## 3. Target users

- medicinal chemistry teams
- translational biology groups
- research teams with narrow, high-value target classes
- organizations prioritizing lead quality over screening breadth

## 4. Core user problem

Many early-stage systems generate molecules that appear promising in silico but fail in real biology. Too often, the system only validates one assay and misses deeper issues such as selectivity, retention of activity, or safety risk.

## 5. Functional overview

### 5.1 Target and design layer
- target tractability review
- disease-relevant biology screening
- chemical space definition and scaffold controls
- AI candidate generation with high-quality property constraints

### 5.2 Assay and validation layer
- CRO protein expression and assay readiness
- SPR validation for direct binding
- enzyme activity and biochemical potency screening
- orthogonal assay confirmation for shortlisted compounds

### 5.3 Selectivity and retained activity layer
- target-family selectivity testing
- retained activity under alternative conditions
- counter-screening and off-target assessment
- mechanism-specific validation

### 5.4 Safety and ADMET layer
- permeability and solubility analysis
- CYP interactions and metabolic risk
- hERG and organ-specific toxicity triage
- physicochemical risk scoring

### 5.5 Synthesis gate
- route feasibility analysis
- medicinal chemistry analog design
- analog prioritization around synthetic constraints

### 5.6 Feedback loop
- poor selectivity triggers redesign around scaffold and binding mode
- weak biochemical potency triggers structural search or assay correction
- ADMET or toxicity failure routes back to chemical design and property optimization
- poor synthesis feasibility triggers analog redesign

## 6. Key decision gates

- target relevance and tractability
- assay readiness and protein quality
- direct binding quality
- potency quality and retained activity
- selectivity quality
- ADMET and toxicity risk
- synthesis feasibility

## 7. Value proposition

This pipeline is best for teams seeking higher-quality leads, better biological confidence, and lower late-stage failure rates. It improves the chance that molecules genuinely behave as intended under realistic biological conditions.

## 8. KPI targets

- improve hit-to-lead conversion rate
- reduce late-stage failure rate
- increase likelihood of finding mechanistically valid leads
- reduce wasted chemistry due to early false positives

## 9. Risks

- slower iteration cycles
- narrower design space
- higher need for high-quality biological data and assay discipline

## 10. Recommended deployment strategy

Start with one disease area and one lead series, and build a rigorous assay stack around that space. Focus on data quality and clear decision thresholds before scaling beyond the initial target class.

## 11. Product summary

This PRD is best suited for teams that value lead quality and confidence over throughput. It is a more scientifically rigorous system and is strongly aligned with real-world lead discovery.
